Evidence map›Paper›PMID 35615334›Full record

ArticleMediterranean journal of hematology and infectious diseases2022

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report.

Martina Di Palma, Elio Gentilini, Chiara Masucci, Alessandra Micozzi, Ombretta Turriziani, Antonino Mulè, Robin Foà, Maurizio Martelli, Gabriella D'Ettorre, Saveria Capria and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediterranean journal of hematology and infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Martina Di PalmaDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Elio GentiliniDepartment of Public Health and Infectious Diseases, Sapienza University, Rome.
Chiara MasucciDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Alessandra MicozziDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Ombretta TurrizianiDepartment of Molecular Medicine, Sapienza University, Rome.
Antonino MulèUOC di Oncoematologia, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Robin FoàDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Maurizio MartelliDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Gabriella D'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University, Rome.
Saveria CapriaDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Sabina ChiarettiDepartment of Translational and Precision Medicine, Sapienza University, Rome.
Sapienza University of Rome · ITOspedale Vincenzo Cervello · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of patients with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection is challenging. We describe the clinical history of a 40-year-old male with relapsed B-common ALL who developed Sars-CoV2 prior to treatment initiation with inotuzumab. Since the patient was asymptomatic for COVID-19, the first dose of inotuzumab was administered, followed by remdesivir as prophylaxis. However, a worsening in respiratory findings led to a delay in administering the following doses of inotuzumab. Interestingly, even if the patient did not receive the full inotuzumab cycle, he achieved a complete hematologic remission: furthermore, he spontaneously developed anti-sars-COV2 antibodies. COVID-19 treatment also included convalescent plasma, leading to negativization of the viral load. The patient, after COVID-19 recovery, received a second full cycle of inotuzumab, underwent allogeneic transplantation, and is currently in complete hematologic and molecular remission, in good clinical conditions, five months from allograft.

Indexed as

Acute lymphoblastic leukemiaConvalescent plasmaCOVID-19InotuzumabRemdesevir

Identifiers

PMID35615334
PMCPMC9084234
OpenAlexW4285739894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.